keyword
MENU ▼
Read by QxMD icon Read
search

colorectal cancer and early detection

keyword
https://www.readbyqxmd.com/read/28648086/lower-morbidity-and-improved-outcomes-in-patients-with-screen-detected-colorectal-cancer
#1
David Mansouri
Screening for colorectal cancer is now integrated into the fabric of healthcare systems across the world, as a wealth of evidence exists as regards its benefits in reducing cancer-specific mortality through the detection of early-stage disease. Options for screening include both endoscopic and stool-based tests, with a majority of countries opting for repeated faecal occult blood screening tests (FOBt). These can be either guaiac-based, as is the current system across the UK, or immunoglobulin-based, as is the case in the accompanying article from Spain...
June 26, 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28646456/using-comics-to-promote-colorectal-cancer-screening-in-the-asian-american-and-pacific-islander-communities
#2
Jiayan Linda Wang, Nazia Acevedo, Georgia Robins Sadler
There are unaesthetic aspects in teaching people about the early detection of colorectal cancer using the fecal immunochemical test. Comics were seen as a way to overcome those unaesthetic aspects. This study used the Asian grocery store-based cancer education venue to pilot-test the clarity, cultural acceptability, and alignment of five colorectal cancer education comics intended for publication in Asian American and Pacific Islander (API) community newspapers. After developing the colorectal cancer education comics, API students asked shoppers to review a comic from their collection and provide feedback on how to make the comic clearer and more culturally pertinent to API readers...
June 23, 2017: Journal of Cancer Education: the Official Journal of the American Association for Cancer Education
https://www.readbyqxmd.com/read/28645942/mutational-heterogeneity-in-apc-and-kras-arises-at-the-crypt-level-and%C3%A2-leads-to-polyclonality-in-early-colorectal-tumorigenesis
#3
Mireia Gausachs, Ester Borras, Kyle Chang, Sara González, Daniel Azuara, Axel Delgado Amador, Adriana Lopez-Doriga, F Anthony San Lucas, Xavier Sanjuan, Maria jOSE Paules, Melissa Taggart, Gareth Davies, Erik A Ehli, Jerry Fowler, Victor Moreno, Marta Pineda, Y Nancy You, Patrick M Lynch, Conxi Lazaro, Nicholas E Navin, Paul Scheet, Ernest T Hawk, Gabriel Capella, Eduardo Vilar
Purpose:  The majority of genomic alterations causing intratumoral heterogeneity (ITH) in colorectal cancer (CRC) are thought to arise during early stages of carcinogenesis as a burst but only after truncal mutations in APC have expanded a single founder clone. We have investigated if the initial source of ITH is consequent to multiple independent lineages derived from different crypts harboring distinct truncal APC and driver KRAS mutations, thus challenging the prevailing monoclonal monocryptal model. <p>Experimental design: High-depth next-generation sequencing and SNP arrays were performed in whole lesion extracts of 37 FAP colorectal adenomas...
June 23, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28645422/form-of-presentation-natural-history-and-course-of-postoperative-venous-thromboembolism-in-patients-operated-on-for-pelvic-and-abdominal-cancer-analysis-of-the-riete-registry
#4
Ana Belén Bustos Merlo, Juan Ignacio Arcelus Martínez, Jesús Damián Turiño Luque, Beatriz Valero, Aurora Villalobos, Miguel Ángel Aibar, Manuel Monreal Bosch
INTRODUCTION: Venous thromboembolism (VTE) represents a serious complication after oncologic surgery. Recent studies have shown that the risk of VTE persists several weeks after surgery. This study assesses the form of presentation and time course of VTE after abdominal and pelvic cancer surgery. METHODS: Prospective, multicenter, observational study that analyzes data from an international registry (RIETE) that includes consecutive patients with symptomatic VTE...
June 20, 2017: Cirugía Española
https://www.readbyqxmd.com/read/28643319/-progress-of-the-application-of-optical-coherence-tomography-in-gastrointestinal-tumor-surgery
#5
Yongsheng Li, Hao Liu, Haipeng Huang, Yu Zhu, Haijun Deng, Jiang Yu, Site Luo, Li Huo, Li Lin, Huikai Xie, Guoxin Li
Optical coherence tomography (OCT) is a real-time, cross-sectional optical imaging technology. It is analogous to ultrasonography, except that OCT uses light waves instead of sound waves, and can provide three-dimensional morphological images of living tissues with a micrometer resolution. Through the use of endoscopes, needles, catheters and laparoscopes, OCT has demonstrated tremendous imaging potential in tumor surgery. The current studies suggest that OCT has potential for clinical applications in the following fields of gastrointestinal tumor surgery: (1) Early tumor detection and diagnosis: OCT can distinguish differences between polyp tissue, normal tissue and malignant tissue...
June 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28640361/global-and-targeted-serum-metabolic-profiling-of-colorectal-cancer-progression
#6
Yin Long, Beatriz Sanchez-Espiridion, Moubin Lin, Lindsey White, Lopa Mishra, Gottumakkala S Raju, Scott Kopetz, Cathy Eng, Michelle A T Hildebrandt, David W Chang, Yuanqing Ye, Dong Liang, Xifeng Wu
BACKGROUND: Patients with colorectal adenoma polyps (PLPs) are at higher risk for developing colorectal cancer (CRC). However, the development of improved and robust biomarkers to enable the screening, surveillance, and early detection of PLPs and CRC continues to be a challenge. The aim of this study was to identify biomarkers of progression to CRC through metabolomic profiling of human serum samples with a multistage approach. METHODS: Metabolomic profiling was conducted with the Metabolon platform for 30 CRC patients, 30 PLP patients, and 30 control subjects, and this was followed by the targeted validation of the top metabolites in an additional set of 50 CRC patients, 50 PLP patients, and 50 controls with liquid chromatography-tandem mass spectrometry...
June 22, 2017: Cancer
https://www.readbyqxmd.com/read/28638257/xrcc1-gene-polymorphisms-and-mir-21-expression-in-patients-with-colorectal-carcinoma
#7
Hanan Fouad, Dina Sabry, Heba Morsi, Hany Shehab, Naglaa F Abuzaid
OBJECTIVE: The objectives of this study were to evaluate the impact of two X-ray repair cross complementing 1 (XRCC1) gene polymorphisms (Arg194Trp and Arg399Gln) on the risk of development of colorectal cancer (CRC) and to assess the expression levels of microRNA-21 (miR-21) in CRC patients. MATERIALS AND METHODS: A case-control cross sectional study was conducted on 50 CRC patients and 50 cancer-free subjects. DNA and miR-21 were extracted from whole blood samples...
June 2017: Eurasian Journal of Medicine
https://www.readbyqxmd.com/read/28632728/downregulation-of-serum-metabolite-gta-446-as-a-novel-potential-marker-for-early-detection-of-colorectal-cancer
#8
Tsuyoshi Hata, Ichiro Takemasa, Hidekazu Takahashi, Naotsugu Haraguchi, Junichi Nishimura, Taishi Hata, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori
BACKGROUND: We previously reported that GTA-446 may be a useful biomarker for early detection of colorectal cancer. In the present study, we confirmed the clinical feasibility of GTA-446 as a screening tool for colorectal cancer with a novel measurement system developed for clinical use. We also improved sensitivity by analysing GTA-446 levels according to gender. METHODS: Serum samples were collected from 225 colorectal cancer patients and 916 healthy volunteers to measure GTA-446 levels by flow injection analysis-mass spectrometry...
June 20, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28629632/rationale-for-immunological-approaches-to-breast-cancer-therapy
#9
Gwennaëlle C Monnot, Pedro Romero
Despite great advances in early detection, as well as surgical resection of breast tumours, breast cancer remains the deadliest cancer for women worldwide. Moreover, its incidence is without pair, accounting for twice as many new cancer cases as the second most prevalent cancer, colorectal carcinoma. There is therefore a strong need for new therapeutic approaches to breast cancers. Immunotherapies are novel treatment modalities which aim to use immune mediators to attack cancerous cells. Recent clinical results show that these may not only mediate tumour regressions but also cures in some cases...
June 16, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28628929/-who-should-provide-persons-with-familial-risk-of-colorectal-cancer-with-information-on-early-detection-the-view-of-those-affected
#10
Jasper Plath, Andrea Siebenhofer, Sylvia Schulz-Rothe, Corina Güthlin
Background Colonoscopy is recommended for persons with a familial risk of colorectal cancer (CRC) before they reach 55 years of age. The aim of this analysis was to ask affected persons aged 40-54 years whether they had found out about early detection of CRC and from which institutions and media they would like to obtain such information. Methods Analysis of data from a cross-sectional study: In a general practice setting, those with a positive family history of CRC were asked to provide written information...
June 19, 2017: Das Gesundheitswesen
https://www.readbyqxmd.com/read/28627551/gold-loaded-nanoporous-iron-oxide-nanocubes-a-novel-dispersible-capture-agent-for-tumor-associated-autoantibody-analysis-in-serum
#11
Sharda Yadav, Mostafa Kamal Masud, Md Nazmul Islam, Vinod Gopalan, Alfred King-Yin Lam, Shunsuke Tanaka, Nam-Trung Nguyen, Md Shahriar Al Hossain, Cuiling Li, Md Yusuke Yamauchi, Muhammad J A Shiddiky
Autoantibodies are produced against tumor associated antigens (TAAs) long before the appearance of any symptoms and thus can serve as promising, non-invasive biomarkers for early diagnosis of cancer. Current conventional methods for autoantibody detection are highly invasive and mostly provide diagnosis in the later stages of cancer. Herein we report a new electrochemical method for early detection of p53 autoantibodies against colon cancer using a strategy that combines the strength of gold-loaded nanoporous iron oxide nanocube (Au@NPFe2O3NC)-based capture and purification while incorporating the inherent simplicity, inexpensive, and portable nature of the electrochemical and naked-eye colorimetric readouts...
June 19, 2017: Nanoscale
https://www.readbyqxmd.com/read/28619831/stool-dna-test-of-methylated-syndecan-2-for-the-early-detection-of-colorectal-neoplasia
#12
Feng Niu, Jialing Wen, Xinhui Fu, Chujun Li, Rongsong Zhao, Shan Wu, Hao Yu, Xianglin Liu, Xia Zhao, Side Liu, Xinying Wang, Jianping Wang, Hongzhi Zou
BACKGROUND: While the incidence of colorectal cancer (CRC) is steadily increasing, screening for CRC with conventional approaches is not routinely performed in China. Noninvasive screening methods are attractive options to resolve this issue. Syndecan-2 (SDC2) is frequently methylated in CRC. However, the value of a stool test of methylated SDC2 for the detection of CRC is unknown. METHODS: Methylation status of SDC2 was tested in cell lines and 398 colorectal tissue samples, and further evaluated with 497 stool samples, including 196 from CRC patients, 122 from adenoma patients, and 179 from normal individuals, using real-time methylation-specific PCR (qMSP)...
June 15, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28618397/meta-analysis-of-the-mutational-status-of-circulation-tumor-cells-and-paired-primary-tumor-tissues-from-colorectal-cancer-patients
#13
Yong Liu, Stefano Meucci, Liming Sheng, Ulrich Keilholz
As predictive markers for anti-EGFR therapy, KRAS and BRAF mutations are routinely detected in primary and metastatic colorectal cancer (CRC) cells, but seldom in circulating tumor cells (CTCs). Detecting mutations in CTCs could help explain mutational differences between tumor cells at local sites and distant metastases, thereby improving treatment outcomes. Here, we conducted a systematic review and meta-analysis to compare KRAS and BRAF mutations in paired CTCs and primary tumors from CRC patients, to detect any possible discordance...
May 26, 2017: Oncotarget
https://www.readbyqxmd.com/read/28611339/policy-of-screening-for-colorectal-cancer-in-saudi-arabia-a-prospective-analysis
#14
Abdulrahman A Aljumah, Abdulrahman M Aljebreen
Colorectal cancer (CRC) is one of the most common cancers worldwide. Several policies of CRC screening are available in different countries. The idea of screening is to identify patients at risk by detection of precancerous and small cancers early enough before they become advanced. In Saudi Arabia (SA), there is no countrywide policy for CRC screening despite the increasing incidence of the disease. Screening for CRC is a multidisciplinary approach that requires education programs, substantial financial support, several logistic measures, and predetermined resources before implementing such a program...
May 2017: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/28608814/predicting-outcome-and-therapy-response-in-mcrc-patients-using-an-indirect-method-for-ctcs-detection-by-a-multigene-expression-panel-a-multicentric-prospective-validation-study
#15
Yolanda Vidal Insua, Juan de la Cámara, Elena Brozos Vázquez, Ana Fernández, Francisca Vázquez Rivera, Mª José Villanueva Villanueva Silva, Jorge Barbazán, Laura Muinelo-Romay, Sonia Candamio Folgar, Alicia Abalo, Rafael López-López, Miguel Abal, Lorena Alonso-Alconada
Colorectal cancer (CRC) is one of the major causes of cancer-related deaths. Early detection of tumor relapse is crucial for determining the most appropriate therapeutic management. In clinical practice, computed tomography (CT) is routinely used, but small tumor changes are difficult to visualize, and reliable blood-based prognostic and monitoring biomarkers are urgently needed. The aim of this study was to prospectively validate a gene expression panel (composed of GAPDH, VIL1, CLU, TIMP1, TLN1, LOXL3 and ZEB2) for detecting circulating tumor cells (CTCs) as prognostic and predictive tool in blood samples from 94 metastatic CRC (mCRC) patients...
June 13, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28604623/dynamic-contrast-enhanced-ultrasound-of-colorectal-liver-metastases-as-an-imaging-modality-for-early-response-prediction-to-chemotherapy
#16
Marie Benzon Mogensen, Martin Lundsgaard Hansen, Birthe Merete Henriksen, Thomas Axelsen, Ben Vainer, Kell Osterlind, Michael Bachmann Nielsen
Our aim was to investigate whether dynamic contrast-enhanced ultrasound (DCE-US) can detect early changes in perfusion of colorectal liver metastases after initiation of chemotherapy. Newly diagnosed patients with colorectal cancer with liver metastases were enrolled in this explorative prospective study. Patients were treated with capecitabine or 5-fluorouracil-based chemotherapy with or without bevacizumab. DCE-US was performed before therapy (baseline) and again 10 days after initiation of treatment. Change in contrast-enhancement in one liver metastasis (indicator lesion) was measured...
June 12, 2017: Diagnostics
https://www.readbyqxmd.com/read/28600478/clinical-implications-of-monitoring-circulating-tumor-dna-in-patients-with-colorectal-cancer
#17
Lone V Schøler, Thomas Reinert, Mai-Britt W Ørntoft, Christine Gaasdal Kassentoft, Sigrid S Árnadóttir, Søren Vang, Iver Nordentoft, Michael Knudsen, Philippe Lamy, Ditte Andreasen, Frank V Mortensen, Anders Riegels Knudsen, Katrine Stribolt, Kim Sivesgaard, Peter Mouritzen, Hans Jørgen Nielsen, Søren Laurberg, Torben F Ørntoft, Claus L Andersen
We investigated if detection of circulating tumor DNA (ctDNA) after resection of colorectal cancer (CRC) identifies the patients with the highest risk of relapse, and furthermore, whether longitudinal ctDNA analysis allows early detection of relapse and informs about response to intervention.<br /><br />Experimental Design: In this longitudinal cohort study we used massively parallel sequencing to identify somatic mutations and used these as ctDNA markers to detect minimal residual disease and to monitor changes in tumor burden during a three year follow-up period...
June 9, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28596563/the-performance-of-the-sept9-gene-methylation-assay-and-a-comparison-with-other-crc-screening-tests-a-meta-analysis
#18
Lele Song, Jia Jia, Xiumei Peng, Wenhua Xiao, Yuemin Li
The SEPT9 gene methylation assay is the first FDA-approved blood assay for colorectal cancer (CRC) screening. Fecal immunochemical test (FIT), FIT-DNA test and CEA assay are also in vitro diagnostic (IVD) tests used in CRC screening. This meta-analysis aims to review the SEPT9 assay performance and compare it with other IVD CRC screening tests. By searching the Ovid MEDLINE, EMBASE, CBMdisc and CJFD database, 25 out of 180 studies were identified to report the SEPT9 assay performance. 2613 CRC cases and 6030 controls were included, and sensitivity and specificity were used to evaluate its performance at various algorithms...
June 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28579957/the-epigenomics-of-embryonic-pathway-signaling-in-colorectal-cancer
#19
REVIEW
Curt Balch, Jayaram B Ramapuram, Amit K Tiwari
Colorectal cancer (CRC) is the second-leading cause of cancer death in developed countries. While early detection (e.g., colonoscopy) generally yields excellent outcomes, metastatic and drug-resistant disease is uniformly fatal, and non-compliance for screening remains over 25%. Familial CRCs (10% of total cases) primarily include mutations in the gene APC. Somatic disease is linked to several environmental several risk factors, including mutations in WNT, KRAS, and TGFβ. To reflect the genesis/progression of CRC, a series of five discrete stages, from normal colon mucosa to fully invasive carcinoma, each regulated by specific "gatekeeper" genes, remains well-accepted after 20 years...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28576867/early-evaluation-of-circulating-tumor-dna-as-marker-of-therapeutic-efficacy-in-metastatic-colorectal-cancer-patients-placol-study
#20
Fanny Garlan, Pierre Laurent-Puig, David Sefrioui, Nathalie Siauve, Audrey Didelot, Nasrin Sarafan-Vasseur, Pierre Michel, Geraldine Perkins, Claire Mulot, Hélène Blons, Julien Taieb, Frederic Di Fiore, Valerie Taly, Aziz Zaanan
Purpose. Markers of chemotherapy efficacy in metastatic colorectal cancer (mCRC) are essential for optimization of treatment strategies. We evaluated the applicability of early changes in circulating tumor DNA (ctDNA) as a marker of therapeutic efficacy. <p>Experimental design. This prospective study enrolled consecutive mCRC patients receiving a first- or second-line chemotherapy. CtDNA was assessed in plasma collected before the first (C0), second (C1) and/or third (C2) chemotherapy cycle, using picodroplet-digital PCR assays based either on detection of gene mutation (KRAS, BRAF, TP53) or hypermethylation (WIF1, NPY)...
June 2, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
120581
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"